- Molecular NameBromocriptine
- SynonymBromergocryptine; Bromocriptin; Bromocriptina [INN-Spanish]; bromocriptine; Bromocriptine Mesylate; Bromocriptine Methanesulfonate; Bromocriptinum [INN-Latin]; Bromocryptine; Bromocryptine Mesylate; Bromoergocriptine; Bromoergocryptine
- Weight638.651
- Drugbank_IDDB01200
- ACS_NO25614-03-3
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)3.08
- pkaN/A
- LogD (pH=7, predicted)0.64
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-5.41
- LogSw (predicted, AB/LogsW2.0)14.57
- Sw (mg/ml) (predicted, ACD/Labs)0.0
- No.of HBond Donors2
- No.of HBond Acceptors8
- No.of Rotatable Bonds5
- TPSA84.99
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn ergoline derivative, is a dopamine agonist that is used in the treatment of pituitary tumors, Parkinson's disease (PD) and neuroleptic malignant syndrome.
- Absorption_value28.0
- Absorption (description)Rapidly absorbed after oral administration.
- Caco_2N/A
- Bioavailability5.0
- Protein binding93.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIt undergoes extensive first-pass metabolism by hydrolysis and isomerisation to 2-bromolysergic acid and 2-bromoisolysergic acid, and, by hydroxylation, further oxidation and conjugation to produce a large number of metabolites.
- Half life12~14 h
- Excretion85% bile (faeces). About 7% of a dose is excreted in the urine as metabolites together with a small fraction as unchanged drug. About 70% of a dose is eliminated in the faeces via the bile within 5 days of a single oral dose.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A